386 related articles for article (PubMed ID: 17114492)
1. Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.
Gorden KK; Qiu X; Battiste JJ; Wightman PP; Vasilakos JP; Alkan SS
J Immunol; 2006 Dec; 177(11):8164-70. PubMed ID: 17114492
[TBL] [Abstract][Full Text] [Related]
2. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.
Gorden KK; Qiu XX; Binsfeld CC; Vasilakos JP; Alkan SS
J Immunol; 2006 Nov; 177(10):6584-7. PubMed ID: 17082568
[TBL] [Abstract][Full Text] [Related]
3. Dual or triple activation of TLR7, TLR8, and/or TLR9 by single-stranded oligoribonucleotides.
Forsbach A; Samulowitz U; Völp K; Hofmann HP; Noll B; Tluk S; Schmitz C; Wader T; Müller C; Podszuweit A; Lohner A; Curdt R; Uhlmann E; Vollmer J
Nucleic Acid Ther; 2011 Dec; 21(6):423-36. PubMed ID: 22196370
[TBL] [Abstract][Full Text] [Related]
4. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
5. Poly-thymidine oligonucleotides mediate activation of murine glial cells primarily through TLR7, not TLR8.
Du M; Butchi NB; Woods T; Peterson KE
PLoS One; 2011; 6(7):e22454. PubMed ID: 21811614
[TBL] [Abstract][Full Text] [Related]
6. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells.
Römmler F; Hammel M; Waldhuber A; Müller T; Jurk M; Uhlmann E; Wagner H; Vollmer J; Miethke T
PLoS One; 2015; 10(2):e0116703. PubMed ID: 25695778
[TBL] [Abstract][Full Text] [Related]
7. Comparison of human B cell activation by TLR7 and TLR9 agonists.
Hanten JA; Vasilakos JP; Riter CL; Neys L; Lipson KE; Alkan SS; Birmachu W
BMC Immunol; 2008 Jul; 9():39. PubMed ID: 18652679
[TBL] [Abstract][Full Text] [Related]
8. Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides.
Jurk M; Kritzler A; Schulte B; Tluk S; Schetter C; Krieg AM; Vollmer J
Eur J Immunol; 2006 Jul; 36(7):1815-26. PubMed ID: 16783850
[TBL] [Abstract][Full Text] [Related]
9. TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation.
Bender AT; Tzvetkov E; Pereira A; Wu Y; Kasar S; Przetak MM; Vlach J; Niewold TB; Jensen MA; Okitsu SL
Immunohorizons; 2020 Feb; 4(2):93-107. PubMed ID: 32086319
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
[TBL] [Abstract][Full Text] [Related]
11. The covalent modification and regulation of TLR8 in HEK-293 cells stimulated with imidazoquinoline agonists.
Rajagopal R; Waller AS; Mendoza JD; Wightman PD
Biochem J; 2008 Jan; 409(1):275-87. PubMed ID: 17868034
[TBL] [Abstract][Full Text] [Related]
12. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Gorden KB; Gorski KS; Gibson SJ; Kedl RM; Kieper WC; Qiu X; Tomai MA; Alkan SS; Vasilakos JP
J Immunol; 2005 Feb; 174(3):1259-68. PubMed ID: 15661881
[TBL] [Abstract][Full Text] [Related]
13. TLR7/8 agonists activate a mild immune response in rabbits through TLR8 but not TLR7.
Lai CY; Liu YL; Yu GY; Maa MC; Leu TH; Xu C; Luo Y; Xiang R; Chuang TH
Vaccine; 2014 Sep; 32(43):5593-9. PubMed ID: 25131730
[TBL] [Abstract][Full Text] [Related]
14. Differences in TLR7/8 activation between monocytes and macrophages.
Eng HL; Hsu YY; Lin TM
Biochem Biophys Res Commun; 2018 Feb; 497(1):319-325. PubMed ID: 29448098
[TBL] [Abstract][Full Text] [Related]
15. Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides.
Sackesen C; van de Veen W; Akdis M; Soyer O; Zumkehr J; Ruckert B; Stanic B; Kalaycı O; Alkan SS; Gursel I; Akdis CA
Allergy; 2013; 68(5):593-603. PubMed ID: 23480796
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the neuroinflammatory response to TLR7 stimulation in the brain: comparison of multiple TLR7 and/or TLR8 agonists.
Butchi NB; Pourciau S; Du M; Morgan TW; Peterson KE
J Immunol; 2008 Jun; 180(11):7604-12. PubMed ID: 18490763
[TBL] [Abstract][Full Text] [Related]
17. CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands.
Buza J; Benjamin P; Zhu J; Wilson HL; Lipford G; Krieg AM; Babiuk LA; Mutwiri GK
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):273-82. PubMed ID: 18789542
[TBL] [Abstract][Full Text] [Related]
18. Chemokine, cytokine and type I interferon production induced by Toll-like receptor activation in common variable immune deficiency.
Lollo C; de Moraes Vasconcelos D; Oliveira LMDS; Domingues R; Carvalho GC; Duarte AJDS; Sato MN
Clin Immunol; 2016 Aug; 169():121-127. PubMed ID: 27392462
[TBL] [Abstract][Full Text] [Related]
19. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR; Rao S; Seder RA; Chen M; Graham BS
Vaccine; 2009 May; 27(23):3045-52. PubMed ID: 19428918
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines.
Kuznik A; Bencina M; Svajger U; Jeras M; Rozman B; Jerala R
J Immunol; 2011 Apr; 186(8):4794-804. PubMed ID: 21398612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
